Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • immunotherapy toxicity
Managing Heart Risk from Cancer Immunotherapy: The International Cardio-Oncology Society Position on ICI-Associated Cardiovascular Toxicity
Posted inCardiology news Oncology

Managing Heart Risk from Cancer Immunotherapy: The International Cardio-Oncology Society Position on ICI-Associated Cardiovascular Toxicity

Posted by MedXY By MedXY 11/13/2025
An expert summary of the 2025 ICS position statement on immune checkpoint inhibitor–associated cardiovascular toxic effects, with practical diagnostic and treatment guidance for clinicians and researchers.
Read More
  • The LVAD Paradox in Heart Transplantation: Higher Risk of Primary Graft Dysfunction, Yet Improved Survival Outcomes
  • Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks
  • Beyond a Symptom: Baseline Fatigue as a Clinical Biomarker for Severe and Fatal Cancer Treatment Toxicities
  • Precision in Prevention: The Role of Prediction-Augmented Shared Decision-Making in Enhancing Lung Cancer Screening Uptake
  • Cardiac Myosin Activation Across the Lifespan: Age-Based Efficacy and Safety of Omecamtiv Mecarbil in HFrEF
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in